MA33240B1 - Inhibiteurs de bêta-sécrétase - Google Patents
Inhibiteurs de bêta-sécrétaseInfo
- Publication number
- MA33240B1 MA33240B1 MA34230A MA34230A MA33240B1 MA 33240 B1 MA33240 B1 MA 33240B1 MA 34230 A MA34230 A MA 34230A MA 34230 A MA34230 A MA 34230A MA 33240 B1 MA33240 B1 MA 33240B1
- Authority
- MA
- Morocco
- Prior art keywords
- beta
- secretase inhibitors
- present
- relates
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/46—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
- C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne un composé représenté par la formule structurale suivante ou un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne en outre des compositions pharmaceutiques et des procédés d'utilisation des composés.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21014609P | 2009-03-13 | 2009-03-13 | |
US30754210P | 2010-02-24 | 2010-02-24 | |
PCT/US2010/027173 WO2010105179A2 (fr) | 2009-03-13 | 2010-03-12 | Inhibiteurs de bêta-sécrétase |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33240B1 true MA33240B1 (fr) | 2012-05-02 |
Family
ID=42664888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34230A MA33240B1 (fr) | 2009-03-13 | 2011-10-04 | Inhibiteurs de bêta-sécrétase |
Country Status (28)
Country | Link |
---|---|
US (3) | US8633212B2 (fr) |
EP (2) | EP2801570A1 (fr) |
JP (2) | JP5731414B2 (fr) |
KR (2) | KR101908255B1 (fr) |
CN (1) | CN102348698B (fr) |
AP (1) | AP2866A (fr) |
AR (1) | AR075854A1 (fr) |
AU (1) | AU2010223937B2 (fr) |
BR (1) | BRPI1009333B8 (fr) |
CA (1) | CA2753730C (fr) |
CO (1) | CO6450683A2 (fr) |
DK (1) | DK2406240T3 (fr) |
EA (1) | EA020875B1 (fr) |
EC (1) | ECSP11011398A (fr) |
ES (1) | ES2571057T3 (fr) |
GE (1) | GEP20135964B (fr) |
IL (1) | IL214226A (fr) |
MA (1) | MA33240B1 (fr) |
MX (1) | MX2011009571A (fr) |
NZ (1) | NZ594230A (fr) |
PE (1) | PE20120219A1 (fr) |
PT (1) | PT2406240E (fr) |
SG (1) | SG173466A1 (fr) |
TN (1) | TN2011000400A1 (fr) |
TW (1) | TWI464153B (fr) |
UY (1) | UY32490A (fr) |
WO (1) | WO2010105179A2 (fr) |
ZA (2) | ZA201106002B (fr) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010021680A2 (fr) | 2008-08-19 | 2010-02-25 | Vitae Pharmaceuticals, Inc. | Inhibiteurs de la bêta-sécrétase |
EP2801570A1 (fr) | 2009-03-13 | 2014-11-12 | Vitae Pharmaceuticals, Inc. | Inhibiteurs de la bêta-sécrétase |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
WO2011106414A1 (fr) * | 2010-02-24 | 2011-09-01 | Dillard Lawrence W | Inhibiteurs de la bêta-secrétase |
US8957083B2 (en) | 2010-11-23 | 2015-02-17 | Amgen Inc. | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use |
US8415483B2 (en) * | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
WO2012109165A1 (fr) | 2011-02-07 | 2012-08-16 | Amgen Inc. | Composés de 5-amino-oxazépine et 5-amino-thiazépane en tant qu'antagonistes de la bêta-sécrétase et leurs procédés d'utilisation |
EP2675810A1 (fr) | 2011-02-15 | 2013-12-25 | Amgen Inc. | Composés hétérocycliques spiro-amino-imidazo-condensés en tant que modulateurs de la bêta-secrétase et méthodes d'utilisation |
JP2014526560A (ja) | 2011-09-21 | 2014-10-06 | アムジエン・インコーポレーテツド | β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法 |
US9650336B2 (en) | 2011-10-10 | 2017-05-16 | Astrazeneca Ab | Mono-fluoro beta-secretase inhibitors |
TWI557112B (zh) * | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β-分泌酶抑制劑 |
EP2847177B1 (fr) | 2012-05-09 | 2017-10-11 | Boehringer Ingelheim International GmbH | Methodes pour la preparation d'oxetan-3-ylmethanamines |
AU2013267555A1 (en) | 2012-05-30 | 2014-12-04 | Comentis, Inc. | Chromane compounds |
EP2669286A1 (fr) * | 2012-05-31 | 2013-12-04 | Ares Trading S.A. | Dérivés de spiro tétrahydro-benzothiophène utiles pour le traitement de maladies neuro-dégénératives |
US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000185B2 (en) * | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US10548882B2 (en) * | 2012-06-21 | 2020-02-04 | Astrazeneca Ab | Camsylate salt |
TW201422592A (zh) * | 2012-08-27 | 2014-06-16 | Boehringer Ingelheim Int | β-分泌酶抑制劑 |
US9533986B2 (en) | 2012-09-27 | 2017-01-03 | Portola Pharmaceuticals, Inc. | Bicyclic dihydropyridone kinase inhibitors |
JP2015532282A (ja) | 2012-09-28 | 2015-11-09 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | β−セクレターゼの阻害剤 |
US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US9079832B2 (en) | 2012-11-21 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Process for making N-sulfinyl α-amino amides |
US10550327B2 (en) | 2012-11-21 | 2020-02-04 | Merck Patent Gmbh | Polymerisable compounds and the use thereof in liquid-crystal displays |
ES2655788T5 (es) | 2013-01-28 | 2024-05-22 | Moelnlycke Health Care Ab | Dispositivo de aspiración |
WO2014160775A1 (fr) | 2013-03-26 | 2014-10-02 | Saint Louis University | Compositions et méthodes de traitement de la malaria |
TW201629025A (zh) | 2014-10-07 | 2016-08-16 | 阿斯特捷利康公司 | 化合物及其作為bace抑制劑之用途 |
JP6319805B2 (ja) * | 2014-10-08 | 2018-05-09 | 田岡化学工業株式会社 | スピロビフルオレン骨格を有するジオール化合物およびその製造方法 |
CN106083764B (zh) * | 2016-07-11 | 2018-09-18 | 上海皓元生物医药科技有限公司 | 一种用于制备axl抑制剂的高纯度中间体的手性拆分方法 |
CN110650735A (zh) * | 2017-05-16 | 2020-01-03 | 芝加哥大学 | 通过钯-催化的分子内链烯基化的4,5-螺环的高度非对映选择性结构 |
TWI677493B (zh) * | 2017-06-14 | 2019-11-21 | 日商日本曹達股份有限公司 | 二唑啉化合物及有害生物防除劑 |
KR101969528B1 (ko) | 2017-09-29 | 2019-04-16 | 에스케이텔레콤 주식회사 | 터치 디스플레이를 제어하는 장치와 방법 및 터치 디스플레이 시스템 |
US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
CN108675923B (zh) * | 2018-06-27 | 2021-04-27 | 沅江华龙催化科技有限公司 | 一种由环酮化合物与2-芳基丙烯及二甲亚砜共同构建螺环化合物的方法 |
CN108675922B (zh) * | 2018-06-27 | 2021-04-27 | 沅江华龙催化科技有限公司 | 一种螺环化合物及其合成方法 |
WO2021065898A1 (fr) | 2019-09-30 | 2021-04-08 | 日本ケミファ株式会社 | Dérivé d'azépane |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5745185A (en) * | 1980-07-21 | 1982-03-13 | Eisai Co Ltd | Hydantoin derivative and its preparation |
AU655666B2 (en) * | 1991-08-28 | 1995-01-05 | Pharmacia & Upjohn Company | Spirocyclic benzopyran imidazolines |
WO1995030642A1 (fr) | 1994-05-06 | 1995-11-16 | Pharmacopeia, Inc. | Bibliotheque combinatoire de dihydrobenzopyranes |
RS52883B (en) | 2003-12-15 | 2014-02-28 | Merck Sharp & Dohme Corp. | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) * | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
DE602005017033D1 (de) | 2004-06-16 | 2009-11-19 | Wyeth Corp | Amino-5,5-diphenylimidazolon-derivate zur beta-sekretase-hemmung |
TW200602048A (en) | 2004-06-16 | 2006-01-16 | Wyeth Corp | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase |
EP1804794B1 (fr) | 2004-10-13 | 2013-07-31 | Merck Sharp & Dohme Corp. | Composés de spiropiperidine utilisés comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer |
CN101198609A (zh) | 2005-06-14 | 2008-06-11 | 先灵公司 | 天冬氨酰基蛋白酶抑制剂 |
WO2006138217A1 (fr) | 2005-06-14 | 2006-12-28 | Schering Corporation | Inhibiteurs d'aspartyl protease |
WO2007005404A1 (fr) | 2005-06-30 | 2007-01-11 | Wyeth | DÉRIVÉS D'IMIDAZOLONE PORTANT UN GROUPEMENT HÉTÉROARYLE À 6 CHAÎNONS EN POSITION 5 ET UN GROUPEMENT AMINO, ET LEUR EMPLOI DANS LA RÉGULATION DE LA β-SECRÉTASE |
TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
CN101233274B (zh) | 2005-07-29 | 2011-03-16 | 皇家飞利浦电子股份有限公司 | 从蒸汽熨斗产生蒸汽喷发的方法 |
KR20080050430A (ko) | 2005-09-26 | 2008-06-05 | 와이어쓰 | 베타-세크레타제 (bace) 억제제로서아미노-5-[4-(디플루오로메톡시)페닐]-5-페닐이미다졸론화합물 |
CA2628074C (fr) | 2005-10-25 | 2014-01-14 | Shionogi & Co., Ltd. | Derive aminodihydrothiazine |
US7872009B2 (en) * | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
DE102005057688A1 (de) | 2005-12-01 | 2007-06-14 | Endress + Hauser Flowtec Ag | Vorrichtung zur Bestimmung und/oder Überwachung des Massedurchflusses eines gasförmigen Mediums |
JP2009520027A (ja) | 2005-12-19 | 2009-05-21 | ワイス | 2−アミノ−5−ピペリジニルイミダゾロン化合物およびβ−セクレターゼ調節におけるその使用 |
EP1974278A4 (fr) | 2005-12-20 | 2012-01-04 | Fieldbus Foundation | Systeme et procede pour mettre en oeuvre des systemes instrumentes de securite |
WO2007100536A1 (fr) | 2006-02-24 | 2007-09-07 | Wyeth | COMPOSES DE DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] POUR L'INHIBITION DE LA β-SECRETASE |
US8168641B2 (en) | 2006-06-12 | 2012-05-01 | Schering Corporation | Aspartyl protease inhibitors |
ES2412384T3 (es) * | 2006-07-18 | 2013-07-11 | Astellas Pharma Inc. | Derivado de aminoindano o sal del mismo |
CA2662776A1 (fr) | 2006-09-07 | 2008-03-13 | Merck And Co., Inc. | Inhibiteurs de la spiropiperidine beta-secretase pour le traitement de la maladie d'alzheimer |
TW200831484A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
TW200831091A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
WO2008076043A1 (fr) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Nouveaux 2-amino-5,5-diaryl-imidazol-4-ones |
PE20090160A1 (es) | 2007-03-20 | 2009-02-11 | Wyeth Corp | COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA |
PE20090617A1 (es) | 2007-03-23 | 2009-05-08 | Wyeth Corp | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa |
EP2151435A4 (fr) * | 2007-04-24 | 2011-09-14 | Shionogi & Co | Composition pharmaceutique pour le traitement de la maladie d'alzheimer |
CA2683887A1 (fr) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | Derives d'aminodihydrothiazine substitues par un groupe cyclique ayant une activite inhibitoire contre la production de proteine beta amyloide |
TW200902503A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
MX2010008347A (es) | 2008-02-18 | 2010-11-12 | Hoffmann La Roche | Derivados de 4,5-dihidro-oxazol-2-ilamina. |
TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Bace抑制劑 |
WO2010013302A1 (fr) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Dérivé de spiroaminodihydrothiazine |
EP2318416B1 (fr) | 2008-07-28 | 2013-09-04 | Eisai R&D Management Co., Ltd. | Derives de spiroaminodihydrothiazine |
WO2010021680A2 (fr) * | 2008-08-19 | 2010-02-25 | Vitae Pharmaceuticals, Inc. | Inhibiteurs de la bêta-sécrétase |
BRPI0918449A2 (pt) * | 2008-09-11 | 2019-09-24 | Amgen Inc | compostos de anel espiro-tricíclico como moduladores de beta-secretas e métodos de uso |
US20110224231A1 (en) | 2008-11-23 | 2011-09-15 | Pfizer Inc. | Novel Lactams as Beta Secretase Inhibitors |
EP2801570A1 (fr) * | 2009-03-13 | 2014-11-12 | Vitae Pharmaceuticals, Inc. | Inhibiteurs de la bêta-sécrétase |
WO2011072064A1 (fr) | 2009-12-08 | 2011-06-16 | Array Biopharma Inc. | Spiro[chromane-4,4'-imidazol]ones en tant qu'inhibiteurs de bêta-sécrétase |
WO2011106414A1 (fr) | 2010-02-24 | 2011-09-01 | Dillard Lawrence W | Inhibiteurs de la bêta-secrétase |
TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β-分泌酶抑制劑 |
TW201422592A (zh) | 2012-08-27 | 2014-06-16 | Boehringer Ingelheim Int | β-分泌酶抑制劑 |
JP2015532282A (ja) * | 2012-09-28 | 2015-11-09 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | β−セクレターゼの阻害剤 |
-
2010
- 2010-03-12 EP EP14179286.1A patent/EP2801570A1/fr not_active Withdrawn
- 2010-03-12 SG SG2011054616A patent/SG173466A1/en unknown
- 2010-03-12 EA EA201101026A patent/EA020875B1/ru not_active IP Right Cessation
- 2010-03-12 AU AU2010223937A patent/AU2010223937B2/en not_active Ceased
- 2010-03-12 EP EP10708684.5A patent/EP2406240B1/fr active Active
- 2010-03-12 NZ NZ594230A patent/NZ594230A/xx not_active IP Right Cessation
- 2010-03-12 KR KR1020177032350A patent/KR101908255B1/ko active IP Right Grant
- 2010-03-12 DK DK10708684.5T patent/DK2406240T3/en active
- 2010-03-12 UY UY0001032490A patent/UY32490A/es not_active Application Discontinuation
- 2010-03-12 BR BRPI1009333A patent/BRPI1009333B8/pt not_active IP Right Cessation
- 2010-03-12 US US12/723,137 patent/US8633212B2/en active Active
- 2010-03-12 WO PCT/US2010/027173 patent/WO2010105179A2/fr active Application Filing
- 2010-03-12 MX MX2011009571A patent/MX2011009571A/es active IP Right Grant
- 2010-03-12 JP JP2011554237A patent/JP5731414B2/ja active Active
- 2010-03-12 ES ES10708684T patent/ES2571057T3/es active Active
- 2010-03-12 GE GEAP201012410A patent/GEP20135964B/en unknown
- 2010-03-12 CA CA2753730A patent/CA2753730C/fr not_active Expired - Fee Related
- 2010-03-12 AR ARP100100774A patent/AR075854A1/es unknown
- 2010-03-12 PT PT107086845T patent/PT2406240E/pt unknown
- 2010-03-12 CN CN201080011490.5A patent/CN102348698B/zh not_active Expired - Fee Related
- 2010-03-12 TW TW099107245A patent/TWI464153B/zh not_active IP Right Cessation
- 2010-03-12 KR KR1020117023972A patent/KR20120001756A/ko not_active IP Right Cessation
- 2010-03-12 AP AP2011005913A patent/AP2866A/xx active
- 2010-03-12 PE PE2011001640A patent/PE20120219A1/es not_active Application Discontinuation
-
2011
- 2011-07-21 IL IL214226A patent/IL214226A/en active IP Right Grant
- 2011-08-10 TN TN2011000400A patent/TN2011000400A1/fr unknown
- 2011-08-16 ZA ZA2011/06002A patent/ZA201106002B/en unknown
- 2011-10-04 MA MA34230A patent/MA33240B1/fr unknown
- 2011-10-13 EC EC2011011398A patent/ECSP11011398A/es unknown
- 2011-10-13 CO CO11136105A patent/CO6450683A2/es not_active Application Discontinuation
-
2013
- 2013-12-18 US US14/132,877 patent/US9212153B2/en active Active
-
2015
- 2015-04-09 JP JP2015080118A patent/JP2015147792A/ja active Pending
- 2015-10-15 US US14/883,720 patent/US10336717B2/en not_active Expired - Fee Related
-
2017
- 2017-01-16 ZA ZA2017/00326A patent/ZA201700326B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33240B1 (fr) | Inhibiteurs de bêta-sécrétase | |
MA35452B1 (fr) | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante | |
MA42339A1 (fr) | Modulateurs du récepteur farnésoïde x | |
MX2011013771A (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17. | |
MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
MA33492B1 (fr) | Inhibiteurs de bace | |
EA201171004A1 (ru) | Пиридазиноновые соединения | |
TN2010000052A1 (fr) | Derives de pyrazole et leur utilisation comme inhibiteurs de raf | |
RS54386B1 (en) | ANTIVIRAL UNITS | |
MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
MA34819B1 (fr) | Dérivés bicyclo[3.2.1]octylamide et leurs utilisations | |
MA38390B1 (fr) | Composés tétrahydropyrrolothiazines | |
MA34644B1 (fr) | Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2 | |
MA33358B1 (fr) | Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase | |
ATE542813T1 (de) | 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren | |
EA201201377A1 (ru) | Определенные аминопиридазины, композиции на их основе и способы их использования | |
MA34385B1 (fr) | Composés hétérocycliques condensés comme inhibiteurs de phosphodiestérases (pdes) | |
DK1753723T3 (da) | Substituerede quinolinderivater som mitotiske kinesininhibitorer | |
EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
MA35753B1 (fr) | Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2 | |
WO2007109578A3 (fr) | Gamma lactames substitues en tant qu'agents therapeutiques | |
MA38583A1 (fr) | Dérivés de dolastatine 10 et d'auristatines | |
UA97821C2 (en) | Cyclized derivatives as eg-5 inhibitors | |
EA201270216A1 (ru) | Фармацевтический состав | |
MA34599B1 (fr) | Compositions pharmaceutiques contenant un inhibiteur dgat1 |